Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARD-100
- Development stage
- Preclinical
- Lead developer
- Ardanza Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ARD-100 is an oral, clinical-stage monomethyl fumarate (MMF) prodrug being developed by Ardanza Biopharma (in partnership with Cellix Bio) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Chemically, ARD-100 consists of MMF linked to eicosapentaenoic acid (EPA) via a glycerin spacer. This design allows for gradual esterase-mediated cleavage during intestinal transit, delaying MMF release and reducing the peak plasma concentration (Cmax) while maintaining the daily area under the curve (AUC). This peak-sparing pharmacokinetic profile is designed to improve gastrointestinal tolerability and reduce flushing compared to dimethyl fumarate (DMF) and diroximel fumarate (DRF), thereby enhancing patient adherence.
- Other names
- MMF-EPA conjugatemonomethyl fumarate-eicosapentaenoic acid conjugate
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)KEAP1 (Kelch-like ECH-associated protein 1)
Beyond the preview
Go deeper on ARD-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARD-100.